Can bosutinib treat polycystic kidney disease? How effective is it in treating polycystic kidney disease?

Bosutinib is a second-generation tyrosine kinase inhibitor (TKI) that is currently mainly approved for the treatment of chronic myeloid leukemia (CML), especially for patients who are resistant or intolerant to first-generation TKI. It blocks the growth and spread of leukemia cells by inhibiting BCR-ABL kinase activity. In recent years, with the deepening of research on TKI drugs, some studies have begun to explore the potential of bosutinib in non-tumor diseases, including genetic diseases such as polycystic kidney disease (ADPKD).

Polycystic kidney disease is a common hereditary kidney disease whose pathogenesis involves complex processes such as cell proliferation, cyst formation, and fibrosis. Studies have found that certain tyrosine kinase signaling pathways may be abnormally activated during the pathological process of polycystic kidney disease. Therefore, theoretically, tyrosine kinase inhibitors may have a certain effect in blocking these pathways and delaying the development of cysts. However, current clinical data on bosutinib for the treatment of polycystic kidney disease are still very limited, and most of them remain at the stage of animal experiments or preliminary cell model studies.

Judging from existing research observations, bosutinib has shown certain potential to inhibit cyst growth and improve renal function in animal models. This effect may be related to its regulation of cell signal transduction, anti-inflammation or anti-fibrosis. However, due to the lack of large-scale, long-term human clinical trials, its safety, efficacy and indications in patients with polycystic kidney disease still cannot be confirmed, and it is not recommended by relevant guidelines as a standard treatment drug.

In summary, although bosutinib has shown some potential in the treatment of polycystic kidney disease at the theoretical and basic research levels, it is still not a drug officially recognized for the treatment of polycystic kidney disease. For patients with polycystic kidney disease, the more recommended methods at this stage are still conservative treatments such as hypertension management, diet control and regular follow-up, as well as drugs such as tolvaptan that have been approved to delay the progression of the disease. Before considering trial treatment with targeted drugs such as bosutinib, the pros and cons must be carefully evaluated under the guidance of a professional physician.

Reference materials:https://go.drugbank.com/drugs/DB06616